Tachycardia mediated cardiomyopathy: pathophysiology, mechanisms, clinical features and management.
Tachycardia mediated cardiomyopathy (TMC) is a reversible form of dilated cardiomyopathy that can occur with most supraventricular and ventricular arrhythmias. Despite the plethora of literature describing this entity in animal models, as well as humans, it remains poorly understood. Over the last decade, new etiologies of TMC, such as frequent premature ventricular complexes in normal hearts, have been identified. Recent advances in catheter-based ablation therapies, particularly for atrial fibrillation and ventricular arrhythmias, have added a new dimension to the treatment of this condition. This review describes the pathophysiology, proposed mechanisms, clinical features and management in various arrhythmic conditions.
Einstein Institute for Heart and Vascular Health, Einstein Medical Center, Philadelphia, PA, United States.
Shuchita
S
Gupta
Einstein Institute for Heart and Vascular Health, Einstein Medical Center, Philadelphia, PA, United States; Jefferson Medical College, Philadelphia, PA, United States. Electronic address: figueredov@einstein.edu.
Vincent M
VM
Figueredo
D000818:Animals; D002311:Cardiomyopathy, Dilated / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D006333:Heart Failure / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D013617:Tachycardia, Supraventricular / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D017180:Tachycardia, Ventricular / Q000150:complications / Q000503:physiopathology / Q000628:therapy
Tachyarrhythmias; Tachycardia mediated cardiomyopathy; Tachycardia-induced heart failure